No Yes Ok

Archive

« Older Entries Newer Entries »

Can we train our bodies to fight cancer? Tuesday, September 30th, 2014
While tremendous strides have been made in the fight against cancer – the battle is far from over. For patients identified with early stage cancer today – the diagnosis is not a death sentence. Some forms of cance [...]
LSP raises EUR 80 mln to invest in medical innovations Tuesday, September 30th, 2014
Not for distribution or release directly or indirectly, in or into the United States and Canada. This document is being made available solely for informational purposes, and does not constitute an offer to sell or [...]
Nexstim Launches Next Generation NBS 5 System Thursday, September 18th, 2014
Helsinki, 18 September 2014   Nexstim (the “Company”), a medical technology company focused on Navigated Brain Stimulation (NBS), announces the launch of a new NBS system, NBS 5, for noninvasive presurgic [...]
arGEN-X completes recruitment of first cohort of 15 patients with CD70-positive solid tumors into its Phase 1b expansion trial with ARGX-110 Thursday, September 18th, 2014
18 September 2014   Breda, the Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic a [...]
LSP’s portfolio company Affimed listed on NASDAQ Monday, September 15th, 2014
Munich/Amsterdam, 15 September 2014. It is with great pleasure that today, LSP – the specialist European healthcare investment firm – announces that its portfolio company Affimed was successfully listed on the NAS [...]
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients w... Monday, September 8th, 2014
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8, 2014 - Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for r [...]
Hybrigenics’ patent estate of inhibitors of ubiquitin-specific proteases is expanding Monday, September 8th, 2014
•Hybrigenics’ patent on its fourth chemical family of inhibitors of ubiquitin-specific proteases (USP) is granted in Europe •Hybrigenics’ patent on its first chemical family of USP inhibitors gets three mo [...]
Former LSP company Okairos working on Ebola Friday, August 29th, 2014
A link to the press release can be found here [...]
Nexstim Progresses its Navigated Brain Stimulation Technology in Stroke and Demonstrates Improved Outcomes in Brain Tumor Surgery Thursday, August 28th, 2014
• Study on track and sites selected and initiated in multicenter clinical trial on the therapeutic effects of  NBT® for stroke rehabilitation • Nexstim’s NBS® motor mapping in neurosurgical planning impro [...]
LSP’s portfolio company Sapiens Steering Brain Stimulation acquired by Medtronic for EUR 150 million Tuesday, August 26th, 2014
Amsterdam, the Netherlands, 26 August 2014. LSP (Life Sciences Partners), a leading European investor in health care, today announced the acquisition of its portfolio company Sapiens Steering Brain Stimulation (Sapien [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

Can we train our bodies to fight cancer? Tuesday, September 30th, 2014
While tremendous strides have been made in the fight against cancer – the battle is far from over. For patients identified with early stage cancer today – the diagnosis is not a death sentence. Some forms of cance [...]
LSP raises EUR 80 mln to invest in medical innovations Tuesday, September 30th, 2014
Not for distribution or release directly or indirectly, in or into the United States and Canada. This document is being made available solely for informational purposes, and does not constitute an offer to sell or [...]
Nexstim Launches Next Generation NBS 5 System Thursday, September 18th, 2014
Helsinki, 18 September 2014   Nexstim (the “Company”), a medical technology company focused on Navigated Brain Stimulation (NBS), announces the launch of a new NBS system, NBS 5, for noninvasive presurgic [...]
arGEN-X completes recruitment of first cohort of 15 patients with CD70-positive solid tumors into its Phase 1b expansion trial with ARGX-110 Thursday, September 18th, 2014
18 September 2014   Breda, the Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic a [...]
LSP’s portfolio company Affimed listed on NASDAQ Monday, September 15th, 2014
Munich/Amsterdam, 15 September 2014. It is with great pleasure that today, LSP – the specialist European healthcare investment firm – announces that its portfolio company Affimed was successfully listed on the NAS [...]
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients... Monday, September 8th, 2014
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8, 2014 - Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for r [...]
Hybrigenics’ patent estate of inhibitors of ubiquitin-specific proteases is expanding Monday, September 8th, 2014
•Hybrigenics’ patent on its fourth chemical family of inhibitors of ubiquitin-specific proteases (USP) is granted in Europe •Hybrigenics’ patent on its first chemical family of USP inhibitors gets three mo [...]
Former LSP company Okairos working on Ebola Friday, August 29th, 2014
A link to the press release can be found here [...]
Nexstim Progresses its Navigated Brain Stimulation Technology in Stroke and Demonstrates Improved Outcomes in Brain Tumor Surgery Thursday, August 28th, 2014
• Study on track and sites selected and initiated in multicenter clinical trial on the therapeutic effects of  NBT® for stroke rehabilitation • Nexstim’s NBS® motor mapping in neurosurgical planning impro [...]
LSP’s portfolio company Sapiens Steering Brain Stimulation acquired by Medtronic for EUR 150 million Tuesday, August 26th, 2014
Amsterdam, the Netherlands, 26 August 2014. LSP (Life Sciences Partners), a leading European investor in health care, today announced the acquisition of its portfolio company Sapiens Steering Brain Stimulation (Sapien [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund